{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HAV&page=17",
    "query": {
      "intervention": "HAV",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 1228,
    "total_pages": 123,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HAV&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HAV&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T02:07:58.495Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00039962",
      "title": "Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C",
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "thymalfasin (thymosin alpha 1)",
          "type": "DRUG"
        },
        {
          "name": "PEGinterferon alfa-2a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SciClone Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2002-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-01-15",
      "last_synced_at": "2026-10-23T02:07:58.495Z",
      "location_count": 54,
      "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 43 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00039962"
    },
    {
      "nct_id": "NCT03036839",
      "title": "Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Virus Infection"
      ],
      "interventions": [
        {
          "name": "LDV/SOF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2017-06-27",
      "completion_date": "2019-02-14",
      "has_results": true,
      "last_update_posted_date": "2020-03-02",
      "last_synced_at": "2026-10-23T02:07:58.495Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Detroit, Michigan • The Bronx, New York + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03036839"
    },
    {
      "nct_id": "NCT07636187",
      "title": "Preventive Reminder Ordering AssistanCe Via Texting for Improved Visit Encounters",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Behavior, Health"
      ],
      "interventions": [
        {
          "name": "Pre-visit and post-visit patient messaging",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Default pended order",
          "type": "BEHAVIORAL"
        },
        {
          "name": "EHR communication",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16416,
      "start_date": "2026-07-28",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-23T02:07:58.495Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07636187"
    },
    {
      "nct_id": "NCT01795911",
      "title": "Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Pegylated Interferon Lambda",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ribasphere",
          "type": "DRUG"
        },
        {
          "name": "Daclatasvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 165,
      "start_date": "2013-03",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2015-10-09",
      "last_synced_at": "2026-10-23T02:07:58.495Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01795911"
    },
    {
      "nct_id": "NCT02039219",
      "title": "Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcoholic Hepatitis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "10 mg Obeticholic Acid (OCA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Naga P. Chalasani",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2014-11-03",
      "completion_date": "2018-01-29",
      "has_results": true,
      "last_update_posted_date": "2020-01-28",
      "last_synced_at": "2026-10-23T02:07:58.495Z",
      "location_count": 4,
      "location_summary": "Indianapolis, Indiana • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02039219"
    },
    {
      "nct_id": "NCT02174276",
      "title": "Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Tenofovir disoproxil fumarate",
          "type": "DRUG"
        },
        {
          "name": "GS-4774",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 195,
      "start_date": "2014-07-24",
      "completion_date": "2018-05-30",
      "has_results": true,
      "last_update_posted_date": "2019-06-04",
      "last_synced_at": "2026-10-23T02:07:58.495Z",
      "location_count": 12,
      "location_summary": "Palo Alto, California • Sacramento, California • San Diego, California + 9 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02174276"
    },
    {
      "nct_id": "NCT03226509",
      "title": "Transforming the Cascade Of Hepatitis C Care",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 325,
      "start_date": "2016-09-01",
      "completion_date": "2021-01-14",
      "has_results": false,
      "last_update_posted_date": "2021-01-19",
      "last_synced_at": "2026-10-23T02:07:58.495Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03226509"
    },
    {
      "nct_id": "NCT00050921",
      "title": "Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "somatropin",
          "type": "DRUG"
        },
        {
          "name": "Hepatitis A virus, inactivated",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Keyhole-Limpet Hemocyanin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": null,
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-10-23T02:07:58.495Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00050921"
    },
    {
      "nct_id": "NCT04684914",
      "title": "HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis B, Chronic"
      ],
      "interventions": [
        {
          "name": "HepTcell",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Altimmune, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 87,
      "start_date": "2020-12-26",
      "completion_date": "2024-04-17",
      "has_results": true,
      "last_update_posted_date": "2025-12-08",
      "last_synced_at": "2026-10-23T02:07:58.495Z",
      "location_count": 5,
      "location_summary": "Garden Grove, California • Redwood City, California • San Jose, California + 2 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04684914"
    },
    {
      "nct_id": "NCT05908084",
      "title": "To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "End Stage Renal Disease (ESRD)"
      ],
      "interventions": [
        {
          "name": "Acellular Tissue Engineered Vessel (ATEV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AVF",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Humacyte, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 121,
      "start_date": "2023-09-07",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-23T02:07:58.495Z",
      "location_count": 32,
      "location_summary": "Scottsdale, Arizona • El Centro, California • La Jolla, California + 25 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05908084"
    }
  ]
}